Back to Newsroom

CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize

RNActive® Vaccines Offer Excellent Conditions for Cost-Effective Worldwide Distribution

TÜBINGEN, Germany/BRUSSELS, Belgium, 10 March 2014 – CureVac, a German clinical stage biopharmaceutical company, today announced that it has won the inaugural European Commission Vaccine Prize. The EU has dedicated the prize of two million Euros in an effort to stimulate innovative solutions for vaccine transportation and storage where cold chain cannot be guaranteed. CureVac’s RNActive® vaccine technology, based on messenger RNA (mRNA), convinced the panel of judges of its potential as a novel vaccine platform with the ability to revolutionize the way vaccines will be developed, manufactured and distributed around the world. As a result of their exceptional stability, RNActive® vaccines eliminate the demand for cold chain logistics.